CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Dec. 24, 2021—Streck announced the availability of its MDx-Chex for BCID2 quality control, designed to meet the standards for verifying the performance of sample-to-result molecular tests for sepsis. MDx-Chex for BCID2 evaluates the entire analytical process of the test, including cell lysis, DNA extraction, purification and removal of PCR inhibitors, as well as qPCR amplification, detection, and analysis. The product can be used for assay verification, to track lot-to-lot performance of tests, and to reduce the occurrence of incorrect results due to instrument or assay failures.